BioLizard Secures VLAIO Grant to Enhance AI Solutions in Drug Development

BioLizard, a prominent bioinformatics and data analytics firm, has received funding from Flanders Innovation & Entrepreneurship (VLAIO) to advance its AI-driven biomedical applications. The grant will support the development of a new AI tool designed to optimize drug discovery processes. This tool will utilize large language models (LLMs) to efficiently search and extract valuable insights from both structured and unstructured scientific data, significantly reducing the time required for data review and extraction.

BioLizard's Bio|Verse platform will integrate this sophisticated solution, combining AI capabilities with human expertise. This integration aims to streamline literature analysis, allowing biotech and pharmaceutical companies to accelerate their research processes. The new AI application will offer visual and interactive dashboards for enhanced data interpretation, thereby refining target identification and drug discovery.

With an overwhelming volume of biomedical research published annually, automating the review process has become crucial. BioLizard's CEO, Liesbeth Ceelen, expressed gratitude for the VLAIO grant, emphasizing its role in enabling researchers to focus more on data analysis rather than data gathering. By leveraging this technology, BioLizard aims to support its clients in achieving faster and more reliable insights, enhancing overall drug development outcomes.